KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

November 17, 2020

Primary Completion Date

May 11, 2022

Study Completion Date

July 24, 2025

Conditions
MyelofibrosisPost-PV MFPost-ET MyelofibrosisPrimary Myelofibrosis
Interventions
DRUG

KRT-232

KRT-232, administered by mouth

DRUG

TL-895

TL-895, administered by mouth

Trial Locations (37)

1090

RECRUITING

Meduni Wien, Univ. Klinik für Innere Medizin I, Vienna

1756

RECRUITING

Hematology Clinic Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Sofia

4002

RECRUITING

University Multiprofile Hospital for Active Treatment Dr. Georgi Plovdiv, Plovdiv

5800

RECRUITING

University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski, Pleven, Pleven

8700

RECRUITING

LKH Hochsteiermark, Leoben

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (MSKCC), New York

11000

RECRUITING

Clinical Center of Serbia, Belgrade

21000

RECRUITING

Clinical Center of Vojvodina, Novi Sad

25123

RECRUITING

ASST Spedali Civili di Brescia, Brescia

32024

RECRUITING

Lake City Cancer Center, Lake City

35043

RECRUITING

University Hospital Marburg, Department of Hematology, Oncology and Immunology, Marburg

35233

RECRUITING

University of Alabama at Birmingham School of Medicine, Division of Hematology and Oncology, Birmingham

37007

RECRUITING

University Clinical Hospital of Salamanca, Department of Hematology, Salamanca

40138

RECRUITING

Polyclinic S. Orsola-Malpighi, Bologna

44093

RECRUITING

CHU Nantes - Hôtel Dieu, Nantes

48121

RECRUITING

Hospital of Ravenna, Operative Unit of Hematology, Ravenna

50134

RECRUITING

Careggi University Hospital, Florence

61801

RECRUITING

Carle Cancer Center, Urbana

63310

RECRUITING

Centre Hospitalier Lyon Sud, Pierre-Bénite

71013

RECRUITING

Hospital Casa Sollievo della Sofferenza, Department of Oncology and Hematology, Division of Hematology, Foggia

75475

RECRUITING

Hôpital Saint Louis, Paris

80054

RECRUITING

Chu Amiens Picardie Site Sud, Amiens

87042

RECRUITING

CHU de Limoges Service Hématologie Clinique et Thérapie Cellulaire, Limoges

90603

RECRUITING

The Oncology Institute of Hope, Whittier

07024

RECRUITING

Columbia University Medical Center, Fort Lee

06200

RECRUITING

CHU de Nice Hospital, Nice

06120

RECRUITING

University Hospital Halle (Saale), Department of Internal Medicine IV - Hematology and Oncology, Halle

H-7400

RECRUITING

Moritz Kaposi General Hospital, Department of Hematology, Kaposvár

H-4400

RECRUITING

Szabolcs-Szatmar-Bereg County Hospitals and University Teaching Hospital, Department of Hematology, Nyíregyháza

H-7624

RECRUITING

Medical Center of the University of Pecs, 1st Department of Internal Medicine, Division of Hematology, Pécs

H-8000

RECRUITING

Fejer County St. Gyorgy University Teaching Hospital, Department of Internal Medicine III, Hematology, Székesfehérvár

85-168

RECRUITING

Jan Biziel University Hospital #2 in Bydgoszcz, Department of Hematology, Bydgoszcz

40-519

RECRUITING

Pratia Onkologia Katowice, Katowice

35-055

RECRUITING

Frederic Chopin Provincial Teaching Hospital No. 1 in Rzeszow, Department of Hematology, Rzeszów

76-200

RECRUITING

Slupsk Provincial Specialist Hospital n.a. Janusz Korczak, Department of Hematology, Słupsk

87-100

RECRUITING

Nasz Lekarz Medical Outpatient Clinics Slawomir Jeka, Torun

08003

RECRUITING

Hematologia Clínica, Barcelona

Sponsors
All Listed Sponsors
collaborator

Telios Pharma, Inc.

INDUSTRY

lead

Kartos Therapeutics, Inc.

INDUSTRY

NCT04640532 - KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF | Biotech Hunter | Biotech Hunter